Overview

Study of Safety and Efficacy of MY008211A in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Who Are Naive to Complement Inhibitor Therapy

Status:
RECRUITING
Trial end date:
2025-12-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the efficacy of MY008211A compared to eculizumab in PNH patients.
Phase:
PHASE3
Details
Lead Sponsor:
Wuhan Createrna Science and Technology Co., Ltd
Treatments:
eculizumab